Top ▲

keratoconjunctivitis sicca

Disease ID:1203
Name:keratoconjunctivitis sicca
Associated with:0 target
2 immuno-relevant ligands
dry eye disease | KCS | keratitis sicca
A dry eye syndrome characterised by a deficiency of aqueous tear film over the ocular surface; symptoms include inflammation of the cornea and surrounding tissues from drying, which can lead to damage of the ocular surface. and visual disturbance.
Database Links
Disease Ontology: DOID:12895


No target related data available for keratoconjunctivitis sicca


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approved drug for keratoconjunctivitis sicca.
Clinical Use: Lifitegrast is a topical integrin antagonist approved by the US FDA (July 2016) for the treatment of keratoconjunctivitis sicca (dry eye disease) [3-4].
Phase 3 trial results are published in [3]. | View clinical data
Bioactivity Comments: No specific binding data are provided in [4] to substantiate the lifitegrast/LFA-1 interaction. Target engagement is inferred from biological assays showing inhibition of T cell adhesion and inhibition of inflammatory mediator secretion. In in vitro assays, lifitegrast inhibits Jurkat T cell and HuT 78 T cell adhesion to immobilised ICAM-Ig with IC50s of 2.98nM and 9nM respectively [4].
Lifitegrast was designed to have minimal systemic exposure, to limit action at sites other than at the site of administration [2]. | View biological activity
Immuno Disease Comments: Phase 2 clinical trials NCT00799552 and NCT01675570 are completed.
Clinical Use: Phase 2 trials in dry eye syndrome (keratoconjunctivitis sicca), allergic conjunctivitis, and inflammation and pain following cataract surgery have been completed. | View clinical data
Bioactivity Comments: Bioactivity with respect to effects on occular tissues and occular inflammation in model animals is reported in US20140275247A1, but no target interaction is specified [1]. | View biological activity


Show »

1. Gjorstrup P, Schwartz CE. (2016) Compositions and methods for the treatment of inflammation. Patent number: US20140275247A1. Assignee: ANIDA PHARMA Inc. Priority date: 13/04/2013. Publication date: 19/04/2016.

2. Newman M, Hunke W. (2014) Lfa-1 inhibitor formulations. Patent number: WO2014100135. Assignee: Sarcode Bioscience Inc.. Priority date: 19/12/2012. Publication date: 26/06/2014.

3. Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio Jr FA, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP, OPUS-1 Study Group. (2014) Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology, 121 (2): 475-83. [PMID:24289915]

4. Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J et al.. (2012) Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett, 3 (3): 203-6. [PMID:24900456]